We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A coalition of HIV advocacy groups challenged an attempt by Gilead Sciences to get out of a federal lawsuit against HIV drugmakers accused of delaying competition from generics and branded products. Read More
HHS on Friday submitted its proposed rule on prescription drug imports — a key part of the administration’s strategy to lower drug prices — to the Office of Management and Budget (OMB) for review. Read More
The approval makes the drug the only once-daily PARP inhibitor approved as a monotherapy treatment for recurrent ovarian cancer beyond those with a BRCA mutation. Read More